• Neogen Corporation has released its fourth-quarter and full-year results for the period ended May 31, 2026, reporting revenue of US$225.3 million for the quarter and US$870.4 million for the year, alongside much lower net losses than the prior year despite slightly softer sales.
• The company also issued new fiscal 2027 revenue guidance of US$880 million to US$885 million, signaling management’s current expectations for stabilizing top-line performance after a year of modest revenue contraction.
• With this backdrop of sharply reduced losses and fresh 2027 revenue guidance, we’ll now explore how these updates affect Neogen’s investment narrative.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Neogen Investment Narrative Recap

To own Neogen, you need to believe that tighter global food and animal safety requirements will eventually translate into healthier margins from its core testing platforms. The latest results show revenue essentially flat and losses sharply lower, which supports that margin-improvement story, but the key near term catalyst still hinges on fixing 3M Food Safety integration issues. The biggest risk remains that these operational challenges and softer end markets keep weighing on profitability longer than investors expect.

The new fiscal 2027 revenue guidance of US$880 million to US$885 million is the most relevant update here, because it frames how quickly management expects the business to stabilize after a year of modest revenue contraction. If Neogen can hit those targets while continuing to shrink its losses, it would support the case that integration work and portfolio shifts are starting to stick, though execution risk around Petrifilm and sample collection remains front and center.

Yet beneath the improving loss profile, investors should be aware that ongoing integration inefficiencies and end market softness could still...

Neogen's narrative projects $896.0 million revenue and $102.6 million earnings by 2029.

Uncover how Neogen's forecasts yield a $13.00 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming revenue would shrink roughly 2 percent a year and that Neogen would stay unprofitable, so compared with the current guidance and integration risk, their narrative is much more pessimistic. This latest report could challenge or reinforce those views, and you should expect opinions on Neogen’s future to shift as new data arrives.

Explore 2 other fair value estimates on Neogen - why the stock might be worth just $13.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Neogen research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.